Voyager Therapeutics (VYGR) Share-based Compensation (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Share-based Compensation data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 32.26% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (down 5.55% YoY), and the FY2025 full-year result was $14.8 million, down 17.85% from the prior year.
• Share-based Compensation fell to $2.5 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2025 to a low of $2.1 million in Q3 2022.
• A 5-year average of $3.0 million and a median of $2.9 million in 2023 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 124.62% in 2022, while the deepest fall reached 36.45% in 2022.
• Tracing VYGR's Share-based Compensation over 5 years: stood at $2.2 million in 2022, then climbed by 28.03% to $2.8 million in 2023, then advanced by 23.74% to $3.4 million in 2024, then rose by 3.13% to $3.5 million in 2025, then retreated by 29.34% to $2.5 million in 2026.
• Business Quant data shows VYGR's Share-based Compensation at $2.5 million in Q1 2026, $3.5 million in Q4 2025, and $3.5 million in Q3 2025.